Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.37B

Market cap19.37B

Price-Earnings ratio

13.77

Price-Earnings ratio13.77

Dividend yield

—

Dividend yield—

Average volume

1.28M

Average volume1.28M

High today

$98.02

High today$98.02

Low today

$96.04

Low today$96.04

Open price

$97.36

Open price$97.36

Volume

275.82K

Volume275.82K

52 Week high

$112.29

52 Week high$112.29

52 Week low

$63.51

52 Week low$63.51

Stock Snapshot

The current Incyte(INCY) stock price is $96.97, with a market capitalization of 19.37B. The stock trades at a price-to-earnings (P/E) ratio of 13.77.

On 2026-05-22, Incyte(INCY) stock traded between a low of $96.04 and a high of $98.02. Shares are currently priced at $96.97, which is +1.0% above the low and -1.1% below the high.

The Incyte(INCY)'s current trading volume is 275.82K, compared to an average daily volume of 1.28M.

During the past year, Incyte(INCY) stock moved between $63.51 at its lowest and $112.29 at its peak.

INCY News

TipRanks 57m

Incyte’s Ruxolitinib Cream Delivers Strong Phase 3b Eczema Data, Supporting Dermatology Upside for INCY

Incyte (INCY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel...

TipRanks 15h

Top Incyte Insider Makes Major Move With Fresh Stock Sale

New insider activity at Incyte ( (INCY) ) has taken place on May 21, 2026. Start a conversation with TipRanks’ trusted, data-backed investment intelligence As...

Investing.com 19h

Bernstein initiates Incyte stock coverage with concerns on growth - Investing.com

...

Analyst ratings

55%

of 31 ratings

Buy

35.5%

Hold

54.8%

Sell

9.7%

More INCY News

TipRanks 20h

Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound

Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target The firm is concerned that there is no clear pathway for revenue...

TipRanks 21h

Incyte initiated with a Market Perform at Bernstein

Bernstein initiated coverage of Incyte (INCY) with a Market Perform rating and $99 price target Published first on TheFly – the ultimate source for real-time,...

TipRanks 2d

Incyte, Genesis Molecular AI announce expansion of collaboration

Incyte (INCY) and Genesis Molecular AI announced a significant expansion of their strategic collaboration building and deploying AI to accelerate the discovery...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.